Production of Human CRISPR-Engineered CAR-T Cells
March 15th, 2021
14.3K views
Here, we present a protocol for gene editing in primary human T cells using CRISPR Cas Technology to modify CAR-T cells.
Overview
This article presents a detailed protocol for the generation, activation, expansion, and characterization of human CRISPR-engineered CD19-directed CAR-T cells. The method combines CRISPR-Cas9 genome editing with CAR-T cell therapy, enabling efficient multiplex gene targeting and facilitating translation to clinical applications. The protocol is robust, scalable, and adaptable to various CAR constructs and target genes.
Key Study Components
Area of Science
- Immunotherapy
- Gene editing
- Cellular engineering
- Cancer research
Background
- CAR-T cell therapies have shown significant efficacy in hematological malignancies and are being explored for solid tumors.
- Engineering T cells to express chimeric antigen receptors (CARs) redirects their specificity to tumor cells.
- CRISPR-Cas9 gene editing can enhance the safety and efficacy of CAR-T therapies.
- Efficient protocols are needed for multiplex gene editing and clinical translation.
Purpose of Study
- To describe a reproducible protocol for generating CRISPR-engineered CAR-T cells targeting CD19.
- To enable high-efficiency, multiplex gene editing in human T cells.
- To provide strategies for guide RNA design, selection, and knockout validation.
Methods Used
- Isolation of CD4+ and CD8+ T cells from human PBMCs using selection kits.
- Activation and culture of T cells with IL7 and IL15.
- Preparation of Cas9-sgRNA ribonucleoprotein complexes and electroporation into T cells.
- Lentiviral transduction of CAR constructs.
- Design and validation of guide RNAs using primer design software and TIDE analysis.
- Flow cytometry to assess knockout efficiency and CAR expression.
- Cryopreservation and expansion of edited T cells.
Main Results
- High-efficiency knockout achieved at PDCD1 (90%) and TRAC (98%) loci across multiple donors.
- No significant differences in proliferation, activation, or CAR expression between edited and mock-edited cells.
- Protocol supports multiplex gene editing and is suitable for clinical-scale applications.
- Engineered CAR-T cells are functional and can be used in in vitro and in vivo assays.
Conclusions
- The described protocol enables robust, efficient, and scalable CRISPR-Cas9 engineering of CAR-T cells.
- It is adaptable to various CAR constructs and target genes.
- The approach is being translated to clinical trials for cancer and genetic disorders.
Frequently Asked Questions
What is the main advantage of combining CRISPR-Cas9 with CAR-T cell therapy?
Combining CRISPR-Cas9 with CAR-T cell therapy allows for precise, multiplex gene editing, which can improve the safety and efficacy of CAR-T cells for clinical applications.
How are T cells prepared for CRISPR editing in this protocol?
CD4+ and CD8+ T cells are isolated from PBMCs, combined in a 1:1 ratio, and cultured with IL7 and IL15 before electroporation with Cas9-sgRNA complexes.
How is gene knockout efficiency validated?
Knockout efficiency is assessed using TIDE analysis of Sanger sequencing data and flow cytometry for protein-level validation.
Can this protocol be adapted to other CAR constructs or target genes?
Yes, the protocol is designed to be universally applicable to different CAR constructs and gene targets.
What are the critical steps for successful gene editing in this protocol?
Maintaining accurate molar ratios of Cas9 and sgRNA, adhering to culture conditions, and minimizing time in electroporation solution are critical for high editing efficiency.
What applications are possible with the engineered CAR-T cells?
The engineered CAR-T cells can be used for in vitro cytotoxicity and cytokine assays, as well as in vivo tumor models and clinical trials for cancer and genetic disorders.
Were there any observed effects on T cell proliferation or CAR expression after editing?
No significant changes were observed in proliferation, activation, or CAR expression between edited and mock-edited CAR-T cells.
Executive Industry Relevance
CRISPR-engineered CAR-T cell production enables multiplex gene editing for next-generation adoptive cell therapies, directly addressing biological de-risking and target validation challenges in immuno-oncology pipelines. This protocol supports robust, scalable workflows for functional interrogation of gene targets and CAR constructs, facilitating predictive confidence at key discovery and translational inflection points. Its universal applicability positions it as a reusable platform for both hematological and solid tumor R&D portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional knockout of candidate genes to clarify mechanistic roles in T cell biology.
- Supports multiplexed hypothesis testing for pathway de-risking and target prioritization.
- Facilitates rapid lead gRNA selection and validation for translational continuity.
Screening & Assay Development
- Delivers standardized, reproducible CAR-T cell populations for downstream functional assays.
- Provides quantitative knockout efficiency metrics via TIDE analysis and flow cytometry.
- Prepares engineered cells for high-throughput cytotoxicity and cytokine screening platforms.
Translational & Preclinical Research
- Aligns engineered CAR-T cells with in vitro and in vivo disease-relevant models for efficacy testing.
- Enables continuity from gene editing through preclinical validation and functional assessment.
- Supports risk-adjusted advancement decisions for clinical translation of novel CAR-T constructs.
Pipeline & Workflow Integration
This protocol integrates from early discovery through lead identification and preclinical validation, supporting iterative target interrogation and functional screening.
- Discovery Biology: Provides a platform for null hypothesis testing and mechanistic de-risking of gene targets in T cells.
- Screening: Standardizes CAR-T cell preparation for reproducible, quantitative assay outputs.
- Analytics: Enables precise measurement of knockout efficiency and CAR expression for comparative analyses.
- Translational Research: Bridges engineered cell production with in vivo efficacy and biomarker studies.
- Enterprise Reuse: Offers a scalable, adaptable workflow for diverse CAR constructs and gene targets across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CAR-T development.
- Operational Value: Delivers standardized, reproducible, and scalable gene editing workflows.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling robust target validation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of CAR-T assets.
Implementation Considerations
- Requires expertise in T cell isolation, CRISPR-Cas9 editing, and flow cytometry analytics.
- Demands access to electroporation instrumentation and validated analytical platforms.
- Necessitates strict adherence to culture conditions and reagent ratios for reproducibility.
- Adaptable to various CAR constructs and gene targets with appropriate gRNA design.
- Practical limitations include cell viability and editing efficiency variability across donors.
Biopharma FAQs
Why does null hypothesis testing matter for CRISPR knockout validation?
Null hypothesis testing in CRISPR knockout validation ensures that observed functional changes in CAR-T cells are directly attributable to specific gene edits, supporting rigorous target validation and reducing mechanistic uncertainty in early discovery.
How does independent variable isolation fit the guide RNA screening workflow?
Isolating the effect of each guide RNA during screening allows teams to attribute knockout efficiency and functional outcomes to specific gRNA sequences, enabling precise optimization and selection for downstream CAR-T engineering.
What do quantitative dependent variable measurements enable in CAR-T cell production?
Quantitative measurements such as TIDE analysis and flow cytometry provide objective knockout efficiency and CAR expression data, supporting reproducibility and enabling direct comparison across experimental conditions and donor samples.
Why are replication requirements critical for cross-functional CAR-T development?
Replication across multiple donors and experimental runs ensures that gene editing and CAR-T cell expansion protocols are robust, supporting cross-functional collaboration and reliable transfer of workflows between discovery, translational, and manufacturing teams.
What statistical analysis capabilities are required before implementing multiplex gene editing?
Statistical analysis tools such as TIDE and flow cytometry quantification are essential for validating knockout efficiency, confirming reproducibility, and establishing thresholds for advancement in multiplex CRISPR-CAR-T engineering workflows.
